State Street Holds 5.4% Of Novavax As Partner Payments Help Narrow Its Losses

The passive holding covered 8,827,707 shares, while Novavax's path to adjusted profitability depends on partner product launches.

Share
State Street Holds 5.4% Of Novavax As Partner Payments Help Narrow Its Losses

State Street held a 5.4% stake in Novavax, which develops protein-based vaccines and the Matrix-M immune-response ingredient, according to a passive ownership disclosure filed Tuesday. The position covered 8,827,707 common shares as of September 30, while partner payments helped the vaccine company narrow its losses.

A Stake Without A Control Push

State Street certified that its holding arose from ordinary business activity, rather than an effort to change or influence control of Novavax.

The investor had shared voting power over 8,362,217 shares and sole voting power over none. It reported shared power to dispose of all 8,827,707 shares.

Novavax had a market value of $1.8 billion as of 9:16 a.m. ET Tuesday.

Sanofi's $125 Million Payoff

Novavax's Sanofi partnership delivered a $125 million milestone payment when a late-stage trial of a combined influenza/COVID-19 vaccine triggered the payment. Novavax raised its full-year revenue outlook after receiving the money.

Its third-quarter net loss narrowed to $31 million from $202 million a year earlier. Those results sit against revenue declines and continuing losses; its five-year total shareholder return fell 93.65%.

Sanofi now leads commercialization of Nuvaxovid, Novavax's COVID-19 vaccine, which is authorized by the U.S. FDA, the European Commission and several other countries.

Matrix-M And The Launch Dependency

Novavax earns money from licensing and supplying Matrix-M to partners including Sanofi, Pfizer, Takeda and Serum Institute of India, as well as selling COVID-19 doses under government supply agreements. It produces Matrix-M in Uppsala, Sweden.

The ingredient strengthens the immune response to a vaccine. It also forms part of the R21/Matrix-M malaria vaccine, available in 24 countries as of February 2026. Novavax is conducting early-stage research in shingles and C. diff.

Jim Kelly, Novavax's chief financial officer, said the company expects to cut adjusted research, development, selling and administrative expenses by over $200 million by 2028.

Management said adjusted profitability depends on successful commercial launches of partner products. Those launches remain central to Novavax's effort to move beyond its losses.

Sources

More on Novavax

All Novavax (NVAX) coverage →